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Cancer of the stomach remains endemic in many parts of the world
and continues to present a difficult therapeutic challenge. Although
the incidence of gastric cancer has declined steadily over the past
two decades (Franceschi et al, 1994), predominantly by reduction
in the number of tumours of the antrum (Rios-Castellanos et al,
1992), the overall 5-year survival rate remains in the range of
5–20% with little evidence of improvement despite the introduction
of intensive multi-modality therapies (Kelsen et al, 1996). Surgical
resection is the only potentially curative therapy, although there is
continuing debate about the role of more radical surgery including
extensive lymph node dissection (Cuschieri et al, 1996).
Combination chemotherapy with cytotoxic agents including 5-fluo-
rouracil (5-FU), mitomycin C, doxorubicin, methotrexate, etopo-
side and cisplatin, is a moderately effective means of reducing
tumour bulk in advanced disease, but is not associated with any
significant survival benefits in an adjuvant setting, following
complete resection of gastric cancer (Wils, 1996).
The evaluation of H2-receptor antagonists as anticancer agents
followed from anecdotal observations of tumour regression seen in
patients with ulcerating gastric cancer and mycosis fungoides
(Taylor et al, 1988). The postulated mechanisms of action are
mediated by H2-receptor blockade of suppressor T-lymphocytes,
leading to their functional inhibition and stimulation of natural
killer cell activity (Griswold et al, 1984; Kikuchi et al, 1986) and
antagonism of histamine-stimulated growth (Watson et al, 1993).
Tonnesen et al (1988) conducted a randomized trial and
reported that cimetidine appeared to improve survival in gastric
cancer patients. The British Stomach Cancer Group (BSCG)
established a prospective, double-blind, placebo-controlled trial of
cimetidine in all stages of gastric cancer, to refute or confirm the
observation.
PATIENTS AND METHODS
Between February 1990 and March 1995, 442 patients were
recruited by 59 consultants from 39 hospitals. Each hospital
obtained ethical approval from their local ethics committee before
entering patients into the trial. Patients were eligible if they had
biopsy-proven carcinoma of the stomach and were able to swallow
the medication. There was no specific age limit but patients had to
be fit enough to be entered into the trial and this was defined as a
life expectancy greater than 3 months. Patients who had concur-
rent non-gastric malignancies or ill health due to other causes,
which would limit their prognosis, were excluded. The previous
use of H2-antagonists did not exclude patients from this study.
Written informed consent was gained from all cases.
Data were collected on depth of penetration, resection line
involvement, the absence or presence of lymph node involvement,
and distant metastases in order to allow staging according to the
Birmingham system (Allum et al, 1989a). Randomization was by
phone call to the CRC Trials Unit in Birmingham where the eligi-
bility was checked prior to treatment allocation. Treatments were
allocated to patients in a randomized, double-blind manner with
the clinician, pharmacy and patients unaware of the treatment allo-
cation. After randomization, Smith-Kline Beecham dispatched the
next sealed treatment pack to the hospital pharmacy. The placebo
tablets were identical in appearance and taste to cimetidine tablets;
hence, only Smith-Kline Beecham knew the allocated treatment.
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Correspondence to: MJS LangmanIn general, patients were randomized a few days prior to discharge
from hospital following confirmation of the diagnosis of gastric
adenocarcinoma, and drugs were available as a ‘take home’
prescription.
Patients were randomized to receive tablets of either placebo or
cimetidine in doses of 800 or 400 mg, administered twice daily
until tumour progression, recurrence or death. No restriction was
placed on clinical management of the patients except that concur-
rent known H2-antagonist treatment was not allowed.
Sixty-one months after the study had been initiated, having
recruited 442 patients, it proved impossible to maintain supplies of
the placebo tablets. The trial data monitoring committee agreed
that the blinded treatment code needed to be broken. This was
achieved by matching the treatment allocation held at Smith-Kline
Beecham with the randomization list and blinded treatment pack
code held at the CRC Trials Unit. Patients continuing on the
placebo arm were discontinued from treatment. Those on active
medication with cimetidine continued as per protocol with drugs
administered through pharmacy. At the time the code was broken,
71 cimetidine recipients and 67 placebo recipients were still alive,
of whom 42 cimetidine and 39 placebo recipients were continuing
treatment.
Patients were followed up at regular intervals, according to local
policy. Treatment details were collected at 3-monthly intervals for
the first 2 years and 6-monthly thereafter until the death of the
patient or the censor date.
Statistical methods
The 5-year survival for all cases of gastric cancer is around 5%
(Allum et al, 1989a). The study aimed to recruit 500 patients in
order to be able to detect differences in excess of 5% at the 5%
level of significance with an 80% power. The trial stopped early
when 442 patients had been randomized due to lack of placebo
supplies. This resulted in a slight loss of power when detecting
differences in excess of 5%, as planned, but allows differences in
excess of 10% to be detected with a 95% power.
The analysis was carried out using SAS statistical software
(SAS Institute, SAS Circle, Cary, NC, USA). The primary end
point for analysis was death. Survival was calculated from date of
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Table 1 Patient characteristics on entry to the trial
Treatment group
Cimetidine Cimetidine Placebo Placebo Total
800 mg 400 mg 800 mg 400 mg
Number randomized 107 111 109 115 442
Number ineligible 1 2 2 2 7
Number for analysis 106 109 107 113 435
Sex (%)
Male 77 (73) 75 (69) 77 (72) 84 (74) 313 (72)
Female 29 (27) 34 (31) 30 (28) 29 (26) 122 (28)
Age
Median 67 68 69 67 68
Inter-quartile range 61–76 61–76 62–75 60–75 61–75
Range 33–88 40–85 36–85 23–86 23–88
Stage (%)
I 3 (3) 8 (7.5) 3 (3) 5 (5) 19 (4)
II 15 (14) 17 (16) 16 (15) 19 (17) 67 (16)
III 31 (30) 39 (37) 41 (39) 29 (26) 140 (33)
IVa 19 (18) 8 (7.5) 20 (19) 21 (19) 68 (16)
IVb 36 (35) 34 (32) 26 (24) 37 (33) 133 (31)
Previous H2-receptor antagonist (%)
Yes 36 (37) 31 (32) 33 (35) 38 (39) 138 (36)
No 62 (63) 65 (68) 61 (65) 59 (61) 247 (64)
Other drugs (%)
Yes 17 (17) 19 (19) 19 (19) 15 (14) 70 (18)
No 82 (83) 79 (81) 81 (81) 88 (86) 330 (82)
Time (in days) from diagnosis to randomization
Median 37 36 37 36 36
Inter-quartile range 20–56 24–52 23–56 22–54 22–55
Range 0–699 2–464 0–145 0–109 0–699
Time (in days) from operation to randomization
Median 11 12 12 13 12
Inter-quartile range 7–20 8–28 9–20 8–24 8–23
Range 0–68 1–89 0–90 0–74 0–90
Type of operation (%)
Curative resection 50 (47) 58 (55) 58 (55) 60 (55) 226 (53)
Palliative resection 19 (18) 25 (23) 23 (22) 29 (26) 96 (22)
Inoperable 37 (35) 23 (22) 24 (23) 21 (19) 105 (25)randomization to the date of death or the censor date of 1 March
1997, when the minimum time from entry to the trial was 2 years.
Survival curves were constructed using the method of Kaplan and
Meier (Kaplan and Meier, 1958) and the log-rank test (Peto et al,
1977) was used to assess the differences between groups with an
intention-to-treat analysis. The main comparison was between
those receiving cimetidine and the placebo group. Survival was
also compared for the two different doses. Survival by stage, type
of resection, age and sex were also considered and treatment
comparisons were stratified by these factors. Cox-proporhonal
hazards models were applied to determine the independent pre-
dictors of survival.
RESULTS
Patients
A total of 442 patients were randomized. Seven patients were
excluded from analysis because of ineligibility: two because they
had oesophageal rather than gastric cancer, two with gastric
lymphomas, one with concurrent bladder cancer, one did not have
histological confirmation of disease and one was randomized after
death. There was one protocol violator who was randomized to
receive placebo but was given cimetidine. This patient was
included in the analysis on an intention-to-treat basis.
All 435 eligible patients were followed up for at least 2 years,
except for five patients who were lost to follow-up at 9, 10, 12, 15
and 18 months respectively. Three of these patients were known to
have left the country after being diagnosed with recurrent disease.
At the census date 95 patients were alive. The 75%, median and
25% times between entry to the trial and the census date were 3.0,
4.1 and 5.8 years respectively. The follow-up duration was iden-
tical in each treatment arm.
The patient characteristics are shown in Table 1. The random-
ization was balanced between the treatment groups in terms of sex,
age and stage distribution. The median age for all eligible patients
was 68 years, 72% were males. Forty-seven per cent had stage IV
disease, 32% stage III, 16% stage II and 5% stage I.
Causes of death
A total of 340 patients died during the study: 166 (49%) in the
cimetidine treatment groups and 174 (51%) in the placebo groups.
Three hundred and nine (91%) of the deaths were disease related:
155 in the cimetidine group and 154 in the placebo group. Two
patients on cimetidine died from other cancers (pancreatic cancer
and bronchial). Other causes accounted for 7% of all deaths: eight
taking cimetidine and 16 having placebo. The cause of death was
unknown for five patients (1% of deaths) where death dates only
were obtained: one was taking cimetidine and four placebo.
Survival
The survival curves for cimetidine and placebo recipients are
shown in Figure 1. The median survival for patients receiving
cimetidine was 13 months (95% confidence interval (CI) 9–16
months) and 11 months for the placebo arm (95% CI 9–14
months). There was no significant difference in survival between
the two treatment groups (c2 = 0.65, P = 0.42). The 5-year actu-
arial survival was 21% for those randomized to cimetidine
compared with 18% in the placebo arms (Table 2).
The median survival within the cimetidine group was 13 months
for patients receiving 800 mg twice a day (95% CI 7–20 months)
compared to 13 months (95% CI 8–18 months) for those given
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Figure 1 Survival analysis for each drug. Analysis of 215 patients allocated to cimetidine and 220 patients allocated to placebo (c2 = 0.65, P = 0.42)400 mg twice a day. There was no survival difference between the
two doses of cimetidine (c2 = 0.51, P = 0.46). The 5-year actuarial
survival was 16% for the high dose regime in comparison with
25% on the low dose (Figure 2).
Age (< 60, ³ 60 years, P = 0.005), stage (I, II, III, IVa, IVb, P =
0.0001) and type of resection (curative, palliative, inoperable, P =
0.0001) were shown to be significant predictors of survival with
younger, early stage patients having curative resection tending to
have a better survival. However, there was no survival difference
for sex (P = 0.26) (Table 2). Stratifying by stage, type of resection,
age or sex revealed no significant differences either between treat-
ment and placebo recipients, or between those given the higher and
lower doses of cimetidine. Cox regression identified stage as the
most important predictor of survival with age as the only other
independent factor; stage can be substituted by type of resection.
In all Cox regression analyses treatment was considered but did
not enter the model.
Patients were subdivided as to whether they underwent surgery
with potentially curative (stage I–III) or palliative intent or were
considered inoperable. In those undergoing potentially curative
resection, the median survival for the cimetidine group was
26 months (95% CI 20–41 months) compared to 20 months (95%
CI 16–28 months) for the placebo group (P = 0.44). For those
undergoing palliative resection the median survival was 7 months
for both the cimetidine and placebo groups (95% CI 4–18 months
and 5–10 months respectively). Similarly, for the inoperable patients
median survival was 3 months (95% CI 2–5 months) for both the
cimetidine and placebo group. Stratifying by type of resection
(Figure 3) showed no significant survival advantage for cimetidine
(P = 0.48).
DISCUSSION
Over the past 50 years there has been a significant decline in the
incidence of gastric cancer in males and females in Western
societies. The disease is rare before the age of 40 years but its
incidence rises steadily to reach a peak in the seventh decade.
Although the precise aetiology is unknown, environmental and
genetic factors have been identified which contribute to its devel-
opment (Fuchs and Mayer, 1995). Attempts to improve survival
rates have focused on earlier diagnosis, radical surgery and adju-
vant chemo-radiotherapy.
The BSCG has conducted two trials of adjuvant therapy in the
past. In the first it was not possible to show a benefit from 2 years
of dual-agent chemotherapy (mitomycin C + 5-FU) with or
without induction chemotherapy (Allum et al, 1989b). The second
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Table 2 Survival analysis for treatment and prognostic factors
Survival in % Surviving
months (years)
n No. of % O/E Median 95% CI 1 5
deaths alive
Treatment (c2 = 0.65, P = 0.42)
Cimetidine 215 166 23 0.96 13 9–16 53 21
Placebo 220 174 21 1.04 11 9–14 47 18
Dose of cimetidine (c2 = 0.51, P = 0.46)
800 mg 106 84 21 1.06 13 7–20 53 16
400 mg 109 82 25 0.95 13 8–18 52 25
Dose of placebo (c2 = 0.04, P = 0.84)
800 mg 107 86 20 0.99 12 9–17 48 15
400 mg 113 88 22 1.01 10 6–14 46 21
Sex (c2 = 1.29, P = 0.26)
Male 313 246 21 1.04 11 8–13 47 19
Female 122 94 23 0.91 14 10–21 57 20
Age (years) (c2 = 7.78, P = 0.005)
Under 60 85 57 33 0.73 20 13–38 61 29
60+ 350 283 19 1.08 11 8–13 47 17
Stage (ctrend
2 = 169.36, P < 0.00001)b
I 19 3 84 0.11 a –a 95 78
II 67 35 48 0.42 54 26–a 88 45
III 140 108 23 0.87 16 13–20 63 20
IVa 68 58 15 1.17 10 7–16 42 10
IVb 133 128 4 2.63 3 3–4 17 4
Resection (ctrend
2 = 157.59, P < 0.00001)b
Curative resection 226 146 35 0.62 24 20–31 73 32
Palliative resection 96 84 13 1.37 7 5–10 35 10
Inoperable 105 102 3 2.77 3 2–4 16 2
Surgery with curative intent (stages I–III)
Drug (c2 = 0.60, P = 0.44)
Cimetidine 113 72 36 0.94 26 20–41 75 34
Placebo 113 74 35 1.05 20 16–28 71 30
aSurvival estimate for confidence interval not yet reached due to too few events. bLog-rank test for trend.trial showed no benefit from a 6-month course of triple-agent
chemotherapy (mitomycin C, adriamycin and 5-FU) or radio-
therapy (4500 Gy) over surgery alone (Hallissey et al, 1994).
These trials reflected both the lack of survival benefit and the
significant haematological and renal toxicity seen in several other
trials (Wils, 1996). A meta-analysis of a number of studies has also
failed to demonstrate survival benefits with conventional cytotoxic
agents (Hermans et al, 1993).
The H2-receptor antagonist cimetidine is well tolerated, anec-
dotally linked to healing of malignant gastric ulcers and has been
shown to inhibit suppressor T-lymphocyte function (Griswold et al,
1984; Kikuchi et al, 1986), leading to suggestions that it could have
a useful role as an anticancer agent. We have failed to replicate the
findings of Tonneson et al (1988), who reported median survival to
be improved from 316 days in placebo recipients to 450 days in
those given cimetidine 400 mg twice daily, with a corresponding
improvement in relative survival rates from 28% to 45% at 1 year.
In a study of 222 gastric cancer patients, median survival appeared
markedly greater in those receiving ranitidine 150 mg twice daily
(331 days, 95% CI 232–393 days) compared to those receiving
placebo treatment (187 days, 95% CI 143–269 days) (Primose et al,
1998). However, the median follow-up was only 6 months and the
result was non-significant (P = 0.23). Overall 73 of 107 ranitidine
recipients with staged tumours died compared with 77 of 109
placebo recipients, the small difference being at least accountable
for by a higher proportion of stage I and II cases allocated raniti-
dine. Our study is larger, was able to detect a 10% improvement
with 95% power, and the period of follow-up was considerably
more prolonged with a median of 4 years. Any difference in
survival between cimetidine and placebo recipients in our study is
accounted for by a greater (but non-significant) number of non-
cancer deaths in placebo recipients, and the actual number of
cancer deaths are identical in cimetidine and placebo recipients.
Stratifying for stage or looking at the curative (stages I–III) and
palliative (stages IVa–IVb) patients, also failed to find survival
benefits for cimetidine. Finally, our study showed no evidence of a
dose related difference in survival, as might have been expected if
cimetidine were effective.
Given cimetidine’s inhibition of suppressor T-cells, stimulation
of cell-mediated immunity and the demonstration that histamine
receptors are expressed on a range of cancer cell lines which
mediate cimetidine’s direct anti-proliferative effects in vitro, it is
hardly surprising that there are other clinical studies examining in
different tumour types its anticancer properties. Burtin et al (1988)
performed a small randomized study of 65 patients with a range of
advanced refractory tumours, who were assigned best supportive
care or combination therapy with cimetidine and subcutaneous
injections of histamine. The authors reported improved survival
with the combination regime (172 vs 26 days) and there was a
suggestion that quality of life was also improved. Cimetidine has
also been incorporated into a complex chemo-immunotherapeutic
regime (Gold et al, 1993) which combined infusion of auto-
lymphocytes (ex vivo activated peripheral blood lymphocytes)
from tumour bearing hosts, with cimetidine and cyclophos-
phamide. An early report of activity associated with this regime
(25% response rate in 20 patients with refractory solid tumours)
has not encouraged other groups to take this therapy forward into
randomized trials.
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Figure 2 Survival analysis for cimetidine by dose. Analysis of 106 patients allocated to 800 mg and 109 patients allocated to 400 mg cimetidine (c2 = 0.51,
P = 0.46)
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Renal cell cancer is somewhat responsive to treatment with the
cytokine, a-interferon and is considered an appropriate therapeutic
target for novel immunomodulatory agents. On the basis of two
earlier phase II trials in renal cancer, suggesting that cimetidine
induced a tumour response in 20–30% of patients, Sagaster et al
(1995) conducted a randomized trial in 148 patients with
metastatic renal cancer. Patients received either interferon a
(5 MU 5 ´ weekly, subcutaneously) or interferon plus coumarin
(100 mg daily) and cimetidine (1200 mg daily). No differences
were found in remission rates or survival times suggesting that
coumarin and cimetidine do not enhance the anti-tumour proper-
ties of interferon.
There are interesting data in colorectal cancer, with a small trial
of 35 patients with advanced disease randomized to receive 5-FU-
based chemotherapy alone or in combination with cimetidine
(400 mg twice daily) (Links et al, 1995). There was no difference
in overall response; however, the authors demonstrated that there
was a higher incidence of reduction (> 50% baseline) of the
tumour marker, carcinoembryonic antigen, in the cimetidine-
treated group. The same investigators also performed a small
randomized trial in which 42 patients scheduled for elective
removal of colorectal cancers were randomized to receive cimeti-
dine (400 mg twice daily for 1 week) or control (Adams et al,
1997). They examined lymphocyte infiltration in the resected
tumour specimen and found a significantly higher lymphocyte
response in the cimetidine treated group (56% vs 21%). They also
showed that there is a positive relationship between lymphocyte
infiltration and survival, providing some surrogate of evidence of
the efficacy of cimetidine. A larger randomized trial of 192
colorectal cancer patients undergoing palliative or curative resec-
tions was unable to demonstrate any survival benefit for the cime-
tidine group (Svendsen et al, 1995).
In summary, on the basis of the present study, we conclude that
there is still not enough evidence to show that H2-antagonist treat-
ment is an effective therapy for patients with gastric cancer.
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